liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Assessing the clinical and bacteriological outcomes of vaccination with recombinant Asp14 and OmpA against A. phagocytophilum in sheep
Norwegian Univ Life Sci, Norway.
Norwegian Univ Life Sci, Norway.
Univ Florida, FL 32608 USA.
Norwegian Vet Inst, Norway.
Show others and affiliations
2019 (English)In: Veterinary Immunology and Immunopathology, ISSN 0165-2427, E-ISSN 1873-2534, Vol. 218, article id UNSP 109936Article in journal (Refereed) Published
Abstract [en]

Anaplasma phagocytophilum is a tick borne bacterium, causing disease in sheep and other mammals, including humans. The bacterium has great economic and animal welfare implications for sheep husbandry in Northern Europe. With the prospect of a warmer and more humid climate, the vector availability will likely increase, resulting in a higher prevalence of A. phagocytophilum. The current preventive measures, as pyrethroids acting on ticks or long acting antibiotics controlling bacterial infection, are suboptimal for prevention of the disease in sheep. Recently, the increased awareness on antibiotic- and pyrethorid resistance, is driving the search for a new prophylactic approach in sheep against A. phagocytophilum. Previous studies have used an attenuated vaccine, which gave insufficient protection from challenge with live bacteria. Other studies have focused on bacterial membrane surface proteins like Asp14 and OmpA. An animal study using homologous proteins to Asp14 and OmpA of A. marginate, showed no protective effect in heifers. In the current study, recombinant proteins of Asp14 (rAsp14) and OmpA (rOmpA) of A. phagocytophilum were produced and prepared as a vaccine for sheep. Ten lambs were vaccinated twice with an adjuvant emulsified with rAsp14 or rOmpA, three weeks apart and challenged with a live strain of A. phagocytophilum (GenBank acc.nr M73220) on day 42. The control group consisted of five lambs injected twice with PBS and adjuvant. Hematology, real time qPCR, immunodiagnostics and flow cytometric analyses of peripheral blood mononuclear cells were performed. Vaccinated lambs responded with clinical signs of A.phagocytophilum infection after challenge and bacterial load in the vaccinated group was not reduced compared to the control group. rAsp14 vaccinated lambs generated an antibody response against the vaccine, but a clear specificity for rAsp14 could not be established. rOmpA-vaccinated lambs developed a strong specific antibody response on days 28 after vaccination and 14 days post-challenge. Immunofluorescent staining and flow cytometric analysis of peripheral blood mononuclear monocytes revealed no difference between the three groups, but the percentage of CD4, CD8(+), gamma delta TcR+, lambda-Light chain(+), CD11b(+), CD14(+) and MHC II+ cells, within the groups changed during the study, most likely due to the adjuvant or challenge with the bacterium. Although an antigen specific antibody response could be detected against rOmpA and possibly rAsp14, the vaccines seemed to be ineffective in reducing clinical signs and bacterial load caused by A. phagocytophilum. This is the first animal study with recombinant Asp14 and OmpA aimed at obtaining clinical protection against A. phagocytophilum in sheep.

Place, publisher, year, edition, pages
ELSEVIER , 2019. Vol. 218, article id UNSP 109936
Keywords [en]
Anaplasma phagocytophilum; Recombinant protein; Vaccination; Serological response; Peripheral mononuclear blood cells
National Category
Immunology
Identifiers
URN: urn:nbn:se:liu:diva-162884DOI: 10.1016/j.vetimm.2019.109936ISI: 000500381200009PubMedID: 31590072OAI: oai:DiVA.org:liu-162884DiVA, id: diva2:1382236
Note

Funding Agencies|Norwegian research funding for agriculture and the food industry (Matfondavtalen), Norwegian Association of Sheep and Goat Farmers (NSG), Animalia - the Norwegian Meat and Poultry Research Center and ScandTick Innovation (INTERREG OKS IVA) [244173/E50]

Available from: 2020-01-02 Created: 2020-01-02 Last updated: 2020-01-24

Open Access in DiVA

fulltext(1431 kB)22 downloads
File information
File name FULLTEXT01.pdfFile size 1431 kBChecksum SHA-512
e86c4347693b041f72be76e58dcb2489a7af8ff909a12c4e9d3ef02b57a80a46f8394d13b3ee0984df2ee5028381bb9cc0cec0042c1121bd4170a35e368991e9
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Lindgren, Per-EricWilhelmsson, Peter
By organisation
Division of Microbiology, Infection and InflammationFaculty of Medicine and Health Sciences
In the same journal
Veterinary Immunology and Immunopathology
Immunology

Search outside of DiVA

GoogleGoogle Scholar
Total: 22 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 43 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf